| Mr John Scott Taylor, MD | |
|
407 14th Ave Se, Puyallup, WA 98372-3770 | |
| (253) 697-1848 | |
| Not Available |
| Full Name | Mr John Scott Taylor |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 28 Years |
| Location | 407 14th Ave Se, Puyallup, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770689911 | NPI | - | NPPES |
| 0B51090 | Other | MI | BLUE SHIELD |
| 104441890 | Medicaid | MI | |
| 4786075 | Medicaid | MI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Multicare Good Samaritan Hospital | Puyallup, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mt. Rainier Emergency Physicians, Pllc | 7810980968 | 39 |
| Western Washington Emergency Physicians Pllc | 0749514735 | 73 |
News Archive
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.
As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.
› Verified 8 days ago
| Entity Name | Mt. Rainier Emergency Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538104476 PECOS PAC ID: 7810980968 Enrollment ID: O20040406000189 |
News Archive
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.
As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.
› Verified 8 days ago
| Entity Name | Western Washington Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801352505 PECOS PAC ID: 0749514735 Enrollment ID: O20190625002379 |
News Archive
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.
As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr John Scott Taylor, MD 971 11th Lane Fi, Fox Island, WA 98333-9643 Ph: (253) 238-0567 | Mr John Scott Taylor, MD 407 14th Ave Se, Puyallup, WA 98372-3770 Ph: (253) 697-1848 |
News Archive
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix"), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.
As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.
› Verified 8 days ago
Paul M Billing, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1706 Meridian S, Suite 120, Puyallup, WA 98371 Phone: 253-848-8797 Fax: 253-446-3239 | |
Dr. Eric B Tulley, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-848-6661 Fax: 253-770-5990 | |
Dr. Bobbi A Sipes, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 407 14th Ave Se, 407-14th Ave. Se, Pob 1247, Puyallup, WA 98372 Phone: 253-697-1848 | |
Stephen Edmund Friedrick, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 15th Ave Se, Puyallup, WA 98372 Phone: 253-697-4000 | |
Dr. Michael John Regalado, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-848-6661 Fax: 253-770-5990 | |
Dr. Ted Coleman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 11102 Sunrise Blvd E, Suite 103, Puyallup, WA 98374 Phone: 253-848-8797 Fax: 253-845-0100 | |
Dr. Michael Perry Brook, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 407 14th Ave Se, Puyallup, WA 98372 Phone: 253-697-1848 Fax: 253-770-5990 |